PHAT_OUT_1 [2025-04-02 11:20:29 -0400] 2384 Bytes | 642 tokens | Cum: 642 tkns (8.03% of 8k)
==========================================================================

You're the expert here today. So, I pulled together a bunch of data for you to look over real fast. I'm looking at high-performance stocks today and Phathom Pharmaceuticals (PHAT) hit my radar screen, up to 6.07 from a prev close of 5.12 Do you think its got more juice or is it lacking potential? It's 11:20:28 AM on Wed Apr 02, 2025 -0400 and I have to decide: buy or sell!

--- COMPANY PROFILE ---
Company: Phathom Pharmaceuticals (PHAT)
IPO: IPO date unknown
Shares Outstanding: 69,640,000
Industry: PHARMACEUTICAL PREPARATIONS
Exchange: XNAS

Here's the first list of news for Phathom Pharmaceuticals:

C1 - Apr-01-25 04:15PM - Phathom Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
C2 - Apr-01-25 04:15PM 08:00AM - Phathom Pharmaceuticals Announces Leadership Succession
C3 - Mar-31-25 07:59AM - Actor and Comedian Kenan Thompson Teams Up with Phathom Pharmaceuticals to Raise Awareness About GERD and VOQUEZNA (vonoprazan)
C4 - Mar-07-25 02:08AM - Phathom Pharmaceuticals Inc (PHAT) Q4 2024 Earnings Call Highlights: FDA Approval Boosts ...
C5 - Mar-06-25 09:10AM - Phathom Pharmaceuticals, Inc. (PHAT) Reports Q4 Loss, Tops Revenue Estimates
C6 - Mar-06-25 09:10AM 08:00AM - Phathom Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
C7 - Mar-05-25 07:21AM - Earnings To Watch: Phathom Pharmaceuticals Inc (PHAT) Reports Q4 2024 Result
C8 - Feb-24-25 08:00AM - Phathom Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Business Update on Thursday, March 6, 2025

ONLY 3 RULES for AI:
==============
1) I am a document retrieval system. You are the analyst-investigator.
2) You can request items from my lists to get more info on Phathom Pharmaceuticals (PHAT)
3) AFTER requesting and reading News and SEC filings you'll write a summary, set a score, high price target and headline.
Now, your response should be only 2 or 3 chars. You can say ex., C1, C2, etc., or NEX
The NEX command delivers the NEXt list of News/SEC/Metrics
There are several more lists that use our unified document retrieval system in subsequent prompts.
Your predictons will be compared to reality to rate your accuracy. Try to predict accurately. GOOD LUCK!
Please request a document, read, summarize and score. Say something like "C1".

PHAT_OUT_3 [2025-04-02 11:20:38 -0400] 1098 Bytes | 293 tokens | Cum: 937 tkns (11.71% of 8k)
==========================================================================

Showing C5 (chunk 1 of 5): C5:
**Phathom Pharmaceuticals, Inc. (PHAT) Reports Q4 Loss, Tops Revenue Estimates**
Date: Mar-06-25 09:10AM
Source: (Zacks)
URL: https://finance.yahoo.com/news/phathom-pharmaceuticals-inc-phat-reports-141002072.html

Phathom Pharmaceuticals, Inc. (PHAT) came out with a quarterly loss of $0.79 per share versus the Zacks Consensus Estimate of a loss of $0.98. This compares to loss of $0.80 per share a year ago. These figures are adjusted for non-recurring items.

This quarterly report represents an earnings surprise of 19.39%. A quarter ago, it was expected that this company would post a loss of $1.57 per share when it actually produced a loss of $1.32, delivering a surprise of 15.92%.

Over the last four quarters, the company has surpassed consensus EPS estimates three times.

Phathom Pharmaceuticals , which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

PHAT_OUT_5 [2025-04-02 11:20:39 -0400] 994 Bytes | 287 tokens | Cum: 1355 tkns (16.94% of 8k)
==========================================================================

We present this news so you can catch the big movers from recently breaking news.
Here's a list of news articles you can literally read just by asking.
Usually the first item is the most important.

A1 - 2025-04-01T20:17:03Z - Phathom Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)...
A2 - 2025-04-01T20:32:45Z - Phathom Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Taiwan Ne...
A3 - 2025-04-01T20:27:23Z - Phathom Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)...
A4 - 2025-04-01T20:28:46Z - Phathom Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)...
A5 - 2025-04-01T12:59:00Z - Phathom Pharmaceuticals Appoints Steven Basta To Succeed Terrie Curran As President And CEO...

Request an article by its reference number. (Ex., "A1" gets the first item)
You may also say NEX to go to the next listing.
Response to this prompt limited to 3 chars.

PHAT_OUT_7 [2025-04-02 11:20:44 -0400] 1098 Bytes | 317 tokens | Cum: 1674 tkns (20.93% of 8k)
==========================================================================

Showing A1 (chunk 1 of 3): A1:
**Phathom Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)**Date: 2025-04-01Source: {'uri': 'eagletribune.com', 'dataType': 'news', 'title': 'Eagle-Tribune'}URL: https://www.eagletribune.com/region/phathom-pharmaceuticals-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4/article_b19f30dc-ea34-5583-9dae-19c519dac698.htmlFLORHAM PARK, N.J., April 01, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, today announced that, in connection with the appointment of Steven Basta as President and Chief Executive Officer, the Company's Board of Directors has approved the grant of inducement awards.

The Board of Directors approved the grant to Mr. Basta of a non-qualified stock option to purchase 1,085,000 sha

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

PHAT_OUT_9 [2025-04-02 11:20:44 -0400] 963 Bytes | 275 tokens | Cum: 2027 tkns (25.34% of 8k)
==========================================================================

This is our final list of news.
News AI can literally read just by asking.
Don't miss the breaking news!

B1 - 2025-04-01T12:00:00Z - Phathom Pharmaceuticals Announces Leadership Succession
B2 - 2025-03-06T13:00:00Z - Phathom Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
B3 - 2025-01-29T13:00:00Z - Phathom Pharmaceuticals to Present at the Guggenheim Securities SMID Cap Biotech Conference
B4 - 2024-10-28T12:00:00Z - Phathom Pharmaceuticals to Report Third Quarter 2024 Financial Results and Provide Business Update on Thursday, November 7, 2024
B5 - 2024-08-21T19:16:00Z - The Top 3 Most-Shorted Stocks in August
B6 - 2024-08-08T12:00:00Z - Phathom Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update

Request an article by its reference number. (Ex., "B1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

PHAT_OUT_11 [2025-04-02 11:20:49 -0400] 826 Bytes | 227 tokens | Cum: 2256 tkns (28.20% of 8k)
==========================================================================

Showing B2 (chunk 1 of 1): B2:
**Phathom Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update**Date: Unknown DateSource: Unknown SourceURL: https://www.globenewswire.com/news-release/2025/03/06/3038128/0/en/Phathom-Pharmaceuticals-Reports-Fourth-Quarter-and-Full-Year-2024-Financial-Results-and-Provides-Business-Update.htmlPhathom Pharmaceuticals reported strong commercial performance for its GERD treatment VOQUEZNA, with $55.3 million in 2024 net revenues and over 300,000 filled prescriptions. The company also announced plans to initiate a Phase 2 trial for VOQUEZNA in eosinophilic esophagitis.

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

PHAT_OUT_13 [2025-04-02 11:20:50 -0400] 1094 Bytes | 294 tokens | Cum: 2638 tkns (32.98% of 8k)
==========================================================================

This is our list of SEC filings.
If empty, the search returned no recent filings.

S2 - 2025-03-06 8-K Item2.02 Results of Oper and Fin Cond.

On March 6, 2025, Phathom Pharmaceuticals, Inc. issued a press release announcing its financial results for the quarter and year ended December 31, 2024. A copy of the press release is attached hereto as Exhibit 99.1 and i...

S3 - 2025-03-06 10-K Item 7. Mgts Discussion and Analysis of Fin Cond and Results of Oper.

You should read the following discussion and analysis of our financial condition and results of operations together with our financial statements and related notes included elsewhere ...

S10 - 2024-11-07 10-Q PART I. FINANCI AL INFO

Item 1. Fin St atements (unaudited)

PHATHOM PHARMACEUTICALS, INC.

Bal ance Sheets

(Unaudited)

(in thousands, except share and par value amounts)

September 30, 2024

December 31, 2023

Assets

Curr assets:

Cash and cash eq...

Request filing by its reference number. (Ex., "S1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

PHAT_OUT_15 [2025-04-02 11:20:56 -0400] 1081 Bytes | 268 tokens | Cum: 2908 tkns (36.35% of 8k)
==========================================================================

Showing S2 (chunk 1 of 1): S2:
Item2.02 Results of Operations and Financial Condition.

On March 6, 2025, Phathom Pharmaceuticals, Inc. issued a press release announcing its financial results for the quarter and year ended December 31, 2024. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

In accordance with General Instruction B.2 of Form 8-K, the information in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the Exchange Act), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, except as expressly set forth by specific reference in such filing....

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

PHAT_OUT_17 [2025-04-02 11:21:08 -0400] 5405 Bytes | 1596 tokens | Cum: 4631 tkns (57.89% of 8k)
==========================================================================

This is our set of metrics.
Please analyze the numbers.

+-------------------+-----------------------+-------------------------+-------------------------+
| Volume: 750,080 | Perf Month: 8.24% | Option/Short: Yes / Yes | Sales Y/Y TTM: 8001.47% |
+-------------------+-----------------------+-------------------------+-------------------------+
| Avg Volume: 1.17M | Perf Quarter: -24.50% | Short Float: 37.16% | ROE: - |
+-------------------+-----------------------+-------------------------+-------------------------+
| Rel Volume: 2.28 | Index: RUT | Short Ratio: 12.30 | ROI: -118.94% |
+-------------------+-----------------------+-------------------------+-------------------------+
| RSI (14): 51.68 | Market Cap: 420.61M | Short Interest: 14.36M | Sales Surprise: 18.99% |
+-------------------+-----------------------+-------------------------+-------------------------+
| ATR (14): 0.66 | Shs Outstand: 68.52M | Beta: 0.12 | EPS Surprise: 13.58% |
+-------------------+-----------------------+-------------------------+-------------------------+
| SMA20: 7.08% | Shs Float: 38.63M | Sales Q/Q: 4249.56% | P/E: - |
+-------------------+-----------------------+-------------------------+-------------------------+
| SMA50: 3.99% | Inst Own: 60.25% | Sales past 5Y: 1600.29% | Earnings: Mar 06 BMO |
+-------------------+-----------------------+-------------------------+-------------------------+
| SMA200: -44.39% | Insider Own: 44.53% | Employees: 427 | |
+-------------------+-----------------------+-------------------------+-------------------------+
| Perf Week: -5.92% | Insider Trans: -0.01% | Debt/Eq: - | |
+-------------------+-----------------------+-------------------------+-------------------------+

The next section covers any insider trading.
If this section may be blank due to no recent filings.

Inside Trans: Phathom Pharmaceuticals, Inc. (PHAT) by Parikh Asit (Unknown Title) on 2025-03-13
- Common Stock: 10000 shares at $4.42 (D)

Inside Trans: Phathom Pharmaceuticals, Inc. (PHAT) by Nabulsi Azmi (Chief Operating Officer) on 2025-02-27
- Common Stock: 79200 shares at $0 (D)
- Stock Option (Right to Buy): 55000 shares at $0 (D)

Inside Trans: Phathom Pharmaceuticals, Inc. (PHAT) by Henderson Molly (CFO and CBO) on 2025-02-27
- Common Stock: 72000 shares at $0 (D)
- Stock Option (Right to Buy): 50000 shares at $0 (D)

Inside Trans: Phathom Pharmaceuticals, Inc. (PHAT) by Curran Terrie (President and Chief Executive) on 2025-02-27
- Stock Option (Right to Buy): 342500 shares at $0 (D)

Inside Trans: Phathom Pharmaceuticals, Inc. (PHAT) by Curran Terrie (President and Chief Executive) on 2025-01-21
- Common Stock: 19109 shares at $6.5877 (D)

Inside Trans: Phathom Pharmaceuticals, Inc. (PHAT) by Nabulsi Azmi (Chief Operating Officer) on 2025-01-21
- Common Stock: 7886 shares at $6.5885 (D)

Inside Trans: Phathom Pharmaceuticals, Inc. (PHAT) by Henderson Molly (CFO and CBO) on 2025-01-21
- Common Stock: 6583 shares at $6.5883 (D)

[Company Financial Summary]
[Company Details]
Name: N/A
Market Cap: N/A
Shares Outstanding: N/A
Sector: N/A

[Financial Statements - Latest Quarter]
Total Assets: N/A
Total Liabilities: N/A
Total Equity: N/A
Revenue (Quarter): {'value': 55252000.0, 'unit': 'USD', 'label': 'Revenues', 'order': 100}
Net Income: {'value': -334326000.0, 'unit': 'USD', 'label': 'Net Income/Loss', 'order': 3200}
Earnings Per Share (EPS): N/A

[Price Metrics - Last 30 Days]
Latest Close: 6.12
Average Volume: 1442967.7
30-Day High: 6.69
30-Day Low: 4.22

[Detailed Financials: TTM 2024]
- Total Assets: $378,318,000.0
- Total Liabilities: $631,898,000.0
- Total Equity: $-253,580,000.0
- Current Assets: $360,134,000.0
- Current Liabilities: $85,728,000.0

[Income Statement: TTM 2024]
- Revenue: $55,252,000.00
- Net Income: N/A
- Gross Profit: N/A
- Operating Income: N/A
- Earnings Per Share (EPS): -5.29

[Cash Flow Statement: TTM 2024]
- Net Cash Flow: $-84,131,000.0

[Detailed Financials: FY 2024]
- Total Assets: $378,318,000.0
- Total Liabilities: $631,898,000.0
- Total Equity: $-253,580,000.0
- Current Assets: $360,134,000.0
- Current Liabilities: $85,728,000.0

[Income Statement: FY 2024]
- Revenue: $55,252,000.00
- Net Income: N/A
- Gross Profit: N/A
- Operating Income: N/A
- Earnings Per Share (EPS): -5.29

[Cash Flow Statement: FY 2024]
- Net Cash Flow: $-84,131,000.0
==== END OF FINANCIAL REPORT ====

You are now requested to make a summary analysis.
Save explaining why you didn't have enough information for the final survey.

Now, complete this report with the following:

1) Brief Summary: explain your findings in succinct wording.
2) MARKET_SCORE: If you calculate a 92% likelihood of an upward moves, say: MARKET_SCORE[92]
3) PRICE_TARGET: If you think the high today will be 50% higher, add to the price.
Eg., If the current price is $5.00, add 50%. Thus, PRICE_TARGET[$7.50] -- It should be at or above the current price.
4) Provide a thought-provoking take, 6-10 words, to use for the headline of this news story.
Like this: AI_RPT_HEADLINE: [6-12 words headline for news story, distilled from summary]

1) Brief Summary, 2) MARKET_SCORE, 3) PRICE_TARGET, and 4) AI_RPT_HEADLINE

PHAT_OUT_19 [2025-04-02 11:21:10 -0400] 676 Bytes | 167 tokens | Cum: 5047 tkns (63.09% of 8k)
==========================================================================

Finally, if more data could have improved your confidence which would you have chosen? **Choose one option:**
-> X0 <- Nothing more would have helped my analysis
-> X1 <- More stock-specific news
-> X2 <- More SEC filings (10-K, 10-Q, 8-K) Financials, risk disclosures, and business changes
-> X3 <- More SEC Insider Trading (Form 3, 4, 5) Direct buys/sells from executives and institutions
-> X4 <- Broader sector & market news
-> X5 <- Your past analysis on similar companies (specify metrics)
-> X6 <- More financial metrics
-> X7 <- Your past analysis on this exact company
-> X8 <- Something altogether different (explain...)

PHAT_IN_21 [2025-04-02 11:21:10 -0400] 126 Bytes | 29 tokens | Cum: 5104 tkns (63.80% of 8k)
==========================================================================

====================================
[2025-04-02 11:21:10] # Analysis Completed
Elapsed Time: 42.53 seconds